Biomune Systems Inc. said Thursday that an in vitro test showed itsdrug, Immuno-C, inhibited the Cryptosporidium parasite that leads togastrointestinal diseases.The test, recently developed at Utah State University, allows theevaluation of potential anti-cryptosporidial compounds in a cell culturesystem.Frank Eldridge, vice president, new product development for Biomune,said the test reconfirms its drug's effectiveness against the parasite, andallows a way for the company to concentrate its drug's ingredients. TheSalt Lake City company is in Phase I trials with Immuno-C forcryptosporidiosis.Eldridge told BioWorld the Phase I trial, which will include adetermination of the highest dose tolerated, is moving quickly andefficacy tests should begin in November.Immuno-C is a powdered bovine whey globulin concentrate that, whenreconstituted, has demonstrated significant concentrations ofCryptosporidium antibodies, the company said.Biomune stock (NASDAQ:BIME) was up 44 cents Thursday, closingat $4.88 per share. _ Jim Shrine

(c) 1997 American Health Consultants. All rights reserved.

No Comments